Pregabalin is a structural derivative of the inhibitory neurotransmitter Gammaaminobutyric Acid (GABA) and is used in the treatment of anxiety disorder, neuropathic pain and as an anti-convulsant. The prescription of pregabalin has increased in recent years along with reports of its abuse (especially through taking high doses). Consequently, there is a need to monitor the use of pregabalin in patients prescribed the drug as well as those potentially using it without prescription. Point-of-care testing has been used for many years in monitoring illicit drug use but has only become available recently for pregabalin. In order to validate the effectiveness of this approach, a point-of-care testing device for pregabalin was compared with ‘gold standard’ gas chromatography with mass-spectrometry. The results of a pilot study involving 300 patient urine samples showed that the point-of-care pregabalin testing device was appropriate for determining instances where pregabalin had not been used, but due to the observation of 4% false positives, mass-spectrometry confirmation is recommended (as is usually the case for immunoassay-based approaches, especially in a medico-legal context).
Hamad Al Ghafri1, Abuelgasim Elrasheed1*, Samya Al-Mamari1, Mansoor Assaf1, Mohamed Al Jenaibi1, Hisham Elarabi1, Asma Alawadhi1, Amal Rashid1, Farah Al Meheiri1, Tarek Jawad1, Ahmed Yousif1, and Simon Elliott2,3
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : January 21, 2019